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AbstrACt
Introduction Rapidly expanding digital innovations 
transform the perception, reception and provision of 
health services. Simultaneously, health system challenges 
underline the need for patient-centred, empowering 
and citizen-engaging care, which facilitates a focus on 
prevention and health promotion. Through enhanced 
patient-engagement, patient-provider interactions 
and reduced information gaps, electronic patient-
generated health data (PGHD) may facilitate both 
patient-centeredness and preventive scare. Despite that, 
comprehensive knowledge syntheses on their utilisation 
for prevention and health promotion purposes are lacking. 
The review described in this protocol aims to fill that gap.
Methods and analysis Our methodology is guided by 
Arksey and O’ Malley’s methodological framework for 
scoping reviews, as well as its advanced version by Levac, 
Colquhoun and O’Brien. Seven electronic databases will be 
systematically searched using predefined keywords. Key 
electronic journals will be hand searched, while reference 
lists of included documents and grey literature sources 
will be screened thoroughly. Two independent reviewers 
will complete study selection and data extraction. One 
of the team’s senior research members will act as a 
third reviewer and make the final decision on disputed 
documents. We will include literature with a focus on 
electronic PGHD and linked to prevention and health 
promotion. Literature on prevention that is driven by 
existing discomfort or disability goes beyond the review’s 
scope and will be excluded. Analysis will be narrative and 
guided by Shapiro et al’s adapted framework on PGHD 
flow.
Ethics and dissemination The scoping review described 
in this protocol aims to establish a baseline understanding 
of electronic PGHD generation, collection, communication, 
sharing, interpretation, utilisation, context and impact 
for preventive purposes. The chosen methodology is 
based on the use of publicly available information and 
does not require ethical approval. Review findings will be 
disseminated in digital health conferences and symposia. 
Results will be published and additionally shared with 
relevant local and national authorities.
bACkground 
Emerging and continuously evolving digital 
innovations, such as wireless mobile devices, 
wearables, interactive online platforms 
and electronic data collection tools exert a 
transformative power on many domains of 
human action and interaction.1 2 With acceler-
ating public interest in using electronic tools 
for monitoring, managing and maintaining 
health and well-being, the healthcare market 
becomes an increasingly important field of 
current digital developments.2 The literature 
often refers to the ‘revolutionary enabling’ 
potential of digital innovations in facilitating 
the provision of care, carrying implications 
for patients, healthcare providers and policy 
makers.3 4 
Rapidly expanding digital ecosystems 
are defined as highly disruptive and key to 
improving healthcare while reducing asso-
ciated costs.5 An illustrative example is the 
internet of things, broadly defined as the 
process of connecting and using various 
daily life objects via the internet.6 7 Those 
strengths and limitations of this study
 ► A sensitive and comprehensive search strategy as 
well as a broader analytical scope will enable a 
holistic exploration of electronic patient-generated 
health data (PGHD) use for prevention and health 
promotion, ultimately overcoming existing literature 
fragmentation.
 ► The chosen multidimensional focus of the review’s 
objectives, data extraction and synthesis goes be-
yond merely describing existing PGHD types, to-
wards exploring the roles of those involved and 
their contexts, expanding the topic’s conceptual 
understanding.
 ► As the review’s scope is restricted to health pro-
motion and certain dimensions of prevention, the 
resulting typology of electronic PGHD as well as 
the overall findings might not be applicable beyond 
those domains.
 ► The chosen definition of electronic PGHD, which 
emphasises the aspect of patient control and dis-
tinguishes them from standardised, provider-driven 
tools, will likely influence the results of this study.
 ► Following accepted scoping review standards, the 
review will not formally assess the quality of includ-
ed studies, thus, not allowing for statements on ev-
idence strength.
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technological advances can facilitate the creation of 
valuable health information, as well as its effective use 
for enabling informed decision making and better 
outcomes.4 Simultaneously, the penetration of interac-
tive, dynamic and connected digital tools in daily living 
ultimately expands the roles of consumers, patients 
and care providers.8 Individuals can quantify and track 
their health by digitally capturing vital parameters and 
behavioural data, while healthcare providers can poten-
tially use information generated by new technologies to 
move beyond predominantly curative responsibilities and 
engage in proactive, predictive and preventive action.8
Parallel and closely related to those new possibilities of 
capturing one’s own health parameters is the emerging 
movement of patient-centred or people-centred health-
care.9 10 Traditionally, political decision makers and 
healthcare providers played predominant roles in shaping 
the organisation, management and provision of health-
care.9 11 Modern healthcare systems could benefit from 
higher patient engagement, stronger communication 
channels, efficient information flows and improved adop-
tion of communication and information technologies.12 13 
The Institute of Medicine aims to respond to those needs 
by emphasising the importance of patient-centred care, 
defined as the provision of health services that are sensi-
tively tailored around the needs and preferences of those 
who receive them.14 The global strategy on people-cen-
tred care and integrated health services, prepared by the 
WHO, underlines that a failure to shift towards predom-
inantly consumer-focused practice will inevitably cause 
fragmentation, inefficiencies and long-term unsustain-
ability.9 Similarly, a conceptual model developed by Scholl 
et al15 in 2014 highlights the importance of information 
exchange, active patient involvement and patient empow-
erment. Knowledge transfer, flow and accessibility of 
health data as well as the availability of adequate tech-
nology are core facilitators of patient-centred health 
services.10 Finally, evidence suggests that patient-centred-
ness is associated with higher patient satisfaction and well-
being, which in turn can act as mediating factors towards 
increased patient engagement, health consciousness and 
improved health behaviour.16
The phenomenon of electronic patient-generated 
health data (PGHD) can be positioned on the intersec-
tion between the digital revolution and the patient-cen-
tred care movement. A landmark white paper by the US 
Office of the National Coordinator for Health Informa-
tion Technology (ONC) defines PGHD as ‘health-related 
data—including health history, symptoms, biometric data, 
treatment history, lifestyle choices, and other information—
created, recorded, gathered, or inferred by or from patients or 
their designees (ie, care partners or those who assist them) to 
help address a health concern’.17 18 Electronically captured, 
shared and used PGHD consists of digital information 
that is created outside traditional healthcare contexts.17 18 
For example, individuals at high risk of chronic disease, 
such as sedentary and overweight adults, can self-mon-
itor their physical activity at home and easily share their 
records on interactive, provider-connected online plat-
forms, enabling professional feedback and guidance.19 
Similarly, they can self-capture overall health parameters, 
such as blood pressure, body fat or weight and rapidly 
transmit their values via online-connected devices. Data 
sharing can trigger personalised feedback, customised 
health plans and other persuasive health promotion tech-
niques.20 Those examples amplify the potential of digital 
health and PGHD as a resource in enabling convenient, 
person-centred and cost-effective care that is simultane-
ously proactive, informed and prevention focused.18 21 
Despite this study’s focus on prevention and health promo-
tion, it is crucial to acknowledge the importance and 
applicability of electronic PGHD beyond those domains. 
In fact, such data can facilitate the treatment and reha-
bilitation of increasingly prevalent chronic conditions, 
such as diabetes and heart failure.17 The justification for 
our limited scope has conceptual and practical reasons, 
outlined in the Methods section. A more comprehen-
sive and detailed definition of electronic PGHD is also 
outlined in the methods section of this protocol.
study rAtIonAlE
With increasing prevalence of chronic conditions, proac-
tive and preventive action becomes increasingly vital for 
decision makers, providers as well as patients.22 If imple-
mented effectively, preventive care holds benefits for indi-
viduals, healthcare systems, businesses and society as such. 
It can reduce the risk of disease, discomfort and disability 
while diminishing avoidable expenditure, promoting a 
productive workforce and fostering healthy communi-
ties.22 Achieving successful prevention ultimately requires 
a patient-centred approach that facilitates patient engage-
ment and empowerment as well as meaningful patient–
provider interactions.22 23
Despite significant PGHD-related challenges, evidence 
suggests that digitally enabled PGHD utilisation can facil-
itate both prevention and patient engagement, ultimately 
reducing unnecessary costs and inefficiencies.12 13 17 24–26 
Furthermore, PGHD can add comprehensiveness to the 
assessment of an individual’s health status by narrowing 
information gaps, enhancing patient–provider interac-
tion and reducing data errors.25–27 Research also indi-
cates improved health literacy of patients and consumers, 
as well enhanced knowledge on health conditions and 
risks.24
Despite those benefits, systematically and comprehen-
sively synthesised knowledge on electronic PGHD util-
isation for preventive and health promotion purposes 
appears to be lacking. Existing research is thematically 
fragmented, with most primary studies and reviews 
predominantly focusing on specific types of PGHD at a 
time. For example, the two scoping reviews by Archer et 
al and Davis et al address PGHD in relation to personal 
health records and without a primary focus on preven-
tion and health promotion.28 29 Other studies, such as 
the ongoing Cochrane review by Ammenwerth et al,30 
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capture PGHD as an additional functionality of electronic 
health records, retaining a predominant focus on patient 
access to provider-generated health information. Further 
research syntheses outline the impacts of PGHD-linked 
tools, such as wearables and self-tracking devices, on 
specific risk factors and conditions. For example, Gierisch 
et al summarised the effects of wearable sensing technol-
ogies on physical activity, Fu et al reviewed the impact of 
mobile applications, including electronic monitoring 
and data transmission, on blood glucose levels, while 
Fletscher et al explored the effects of blood pressure 
monitoring on health behaviours.31–33 Existing reviews 
tend to focus on specific forms of PGHD and specific 
risk factors or conditions, often with reference to disease 
management. Our proposed review aims to depart from 
that ‘focused’ approach to holistically address electronic 
PGHD and their use in preventive and health-promoting 
activities. We hypothesise that approaching the liter-
ature with a broader lens and not limiting our focus to 
a specific PGHD format will ultimately enable a holistic 
understanding of where and how successfully PGHD are 
currently used. Finally, our analysis, being equally encom-
passing, may provide insights into how electronic PGHD 
are applied, adding to our knowledge on the contexts 
of PGHD utilisation and how those might contribute 
to improvements and success. Achieving that requires a 
clear framing, for which this protocol provides clear defi-
nitions of key terms and concepts.
study objECtIvEs
The overarching objective of the described study is to 
identify, map and synthesise existing knowledge on the 
generation, collection, communication, sharing, inter-
pretation, utilisation, context and impact of electronic 
PGHD for the facilitation and provision of prevention 
and health promotion. In order to achieve that, as well 
as guide data extraction and synthesis, we have defined 
six targeted objectives, classified into three thematically 
linked components and outlined in box 1.
The first targeted objective ultimately aims to enable 
an improved, comprehensive understanding of PGHD 
while unifying a currently fragmented literature-base 
into a structured, practical typology. The second targeted 
objective aims to facilitate a conceptual understanding 
of how such data are used to offer preventive activities 
and health promotion, emphasising on patient activities, 
provider roles and interactivity. Whenever available, we 
aim to additionally synthesise PGHD-related challenges, 
such as of financial, technical, practical and ethical 
nature. Current gaps in synthesised knowledge related 
to the utilisation and impact of PGHD for prevention 
and health promotion purposes underline the impor-
tance of those elements. Closely related to that, the 
last objective aims to synthesise findings on potential 
impacts and implications of PGHD utilisation on preven-
tion and health promotion-related outcomes as well as 
considerations regarding health equity. Acknowledging 
that differences in technological access, use and literacy 
may replicate social inequities in the digital domain, we 
consider it essential to capture any indication related to 
the potential or actual equity implications of electronic 
PGHD.34 Finally, inherent to our overall aim of mapping 
and synthesising existing knowledge, we expect to draw 
final conclusions on current research trends, as well as 
identify areas with further research needs.
MEthods And AnAlysIs
Conceptual model and definitions
In order to guide and structure the scoping review 
process, we have adapted and used a conceptual frame-
work that was prepared for the US ONC and reported in a 
2012 white paper.17 The original framework visualises the 
flow and context of PGHD, emphasising on data capture, 
transfer and review.17 Our adapted version, provided in 
figure 1, retains the same flow, but additionally empha-
sises the use of PGHD for fostering or providing disease 
prevention, health promotion and patient–provider or 
patient–technology interactions. The framework visu-
alises the generation of different health data types by 
box 1 scoping review objectives
Overarching objective: identify, map and synthesise existing knowledge 
on the generation, collection, communication, sharing, interpretation, 
utilisation, context and impact of electronic patient-generated health 
data (PGHD) for the facilitation and/or provision of preventive activities 
and health promotion.
First targeted objective: provide an overview of PGHD types and tools in 
the context of PGHD for prevention and health promotion:
 ► Identify and map existing types and tools of electronic PGHD. The 
term ‘types’ encompasses data properties and characteristics, as 
well as their preventive and health-promoting aims and functions. 
The term ‘tools’ denotes the used technical infrastructure for PGHD 
creation and utilisation.
Second targeted objective: explore the roles of patients/consumers, 
providers and interactivity in the context of PGHD for prevention and 
health promotion:
 ► Patient/consumer roles: identify and synthesise existing data on pa-
tient/consumer roles, activities and literacy, as well as associated 
barriers and facilitators.
 ► Provider roles: identify and synthesise existing data on provider 
roles, activities, literacy, the integration of such data in their prac-
tice, as well as associated barriers and facilitators.
 ► Interaction: identify and synthesise existing data that link the utili-
sation of electronic PGHD to patient–provider or patient–technology 
interaction.
Third targeted objective: explore the implications of PGHD on health 
outcomes and equity considerations in the context of prevention and 
health promotion:
 ► Health outcomes: if available, synthesise existing data on the impacts 
of PGHD on prevention and health promotion-related outcomes.
 ► Equity considerations: identify whether and what proportion of iden-
tified literature addresses, explores or mentions actual or potential 
PGHD implications on health inequities, for example, by addressing 
the digital divide, sociodemographic characteristics or disadvan-
taged population groups.
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patients, as well as their collection, sharing, communica-
tion and use.
For the purposes of this study, we propose a more 
precise definition of electronic PGHD. Accordingly, the 
term emphasises digital ‘health-related data- including health 
history, symptoms, biometric data, treatment history, lifestyle 
choices, and other information—created, recorded, gathered, or 
inferred by or from patients or their designees (ie, care partners 
or those who assist them) to help address a health concern’ and 
are captured outside traditional healthcare contexts. Our 
definition is limited to predominantly patient or consumer 
driven PGHD, being distinct from data collected through 
standardised, provider-driven questionnaires.17 35 Thus, 
responsibility for capturing, recording and sharing elec-
tronic PGHD lies with the patients and consumers.17 We 
justify that focus on the very nature of prevention and 
health promotion, which requires an empowered health-
care consumer. To comply with our definition, PGHD 
should be available in a digital format when used for the 
intended health-related purposes.
The WHO defines health promotion as any activity 
that aims to empower people in achieving control over 
and enhancing their health.36 Prevention is defined as 
any activity that intentionally aims to impede, reduce or 
delay the occurrence or progress of physical or mental ill 
health, injury and premature death.37 Acknowledging that 
the boundaries between primary, secondary and tertiary 
prevention, as well as their definitions are neither strictly 
defined nor clear, especially when it comes to complex 
chronic conditions, we set our study’s limits around three 
precise prevention elements and health promotion.38 
Thus, to fall within the review’s scope, studies require to 
be placed in the context of at least one of the following 
prevention domains: (1) preventing initial occurrence of 
disease in healthy or high-risk individuals, (2) mitigating 
risk in healthy or high-risk individuals, (3) monitoring 
ongoing disease that is free of apparent symptoms in order 
to avoid progression and (4) promoting health. Clinically 
managing ongoing disease that is manifested by experi-
enced symptoms, discomfort or disability, therapeutic 
interventions and rehabilitation fall outside the review’s 
focus. The reasoning for our narrowed scope is supported 
by conceptual and practical arguments. Conceptually, 
we follow Gordon’s classification that restricts the term 
prevention to primary and secondary levels. However, 
tertiary prevention follows after disease manifestation, 
which is in turn driven by different dynamics and often 
non-distinguishable from therapeutic activities.38 Practi-
cally, keeping preventive and therapeutic interventions 
combined would enormously broaden up our review’s 
scope and lead to an unmanageable amount of literature.
The term provider is defined as any professional that is 
responsible for offering health-related services, including 
health behaviour and lifestyle changes (eg, primary care 
physicians, primary care nurses, pharmacists, specialist 
physicians, physiotherapists, psychologists, wellness 
providers, health and lifestyle coaches). This comprehen-
sive definition aims to maintain a relatively broad scope 
and reduce the likelihood of missing potential valuable 
literature. The review will also incorporate studies where 
healthcare or wellness providers hold secondary roles, 
such as merely monitoring electronic PGHD, or providing 
input on the development of preventive digital PGHD-
based tools, without direct interaction with patients. Even 
though the patient–provider interaction and provider 
involvement might be weak in such scenarios, they are 
Figure 1 Adapted framework for patient-generated health data (PGHD) flow and context for prevention and health 
promotion.17 The framework visualises the flow of PGHD from the patient/consumer (generation and collection stages), passing 
through intermediaries (communication, sharing and interpretation stages) and back to the patient in form of prevention, health 
promotion and interaction (utilisation and impact stages).
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crucial to fully understand the different approaches 
in using electronic PGHD for preventing disease and 
promoting health. Finally, table 1 outlines all PGHD 
dimensions targeted by our review, attaching those to 
corresponding questions and hypothetical examples.
Protocol structure
This protocol is structured and guided by Arksey and 
O’Malley’s methodological framework for scoping 
studies, as well as Levac, Colquhoun and O’Brien’s work 
on advancing that methodology.39 40 The following six 
sections are categorised according to the elements of that 
framework. Those include identifying the research ques-
tion (step 1), identifying relevant studies (step 2), study 
selection (step 3), charting the data (step 4), collating, 
summarising and reporting the results (step 5) and 
stakeholder consultations (step 6).39 40 Furthermore, this 
protocol follows the reporting guidelines of the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
Protocols (PRISMA-P) checklist for systematic review 
protocols.41 Falling beyond the scope of a scoping review, 
the three PRISMA-P elements let aside are the risk of bias 
assessment, meta-biases and evidence strength  (Grading 
Recommendations Assessment, Development and Evalu-
ation (GRADE)).41
step 1: identifying research question
Arksey and O’Malley describe the definition of an appro-
priate research question as a crucial initial step that 
defines and refines the chosen research strategy.39 An 
iterative process of exchange, consultation and literature 
acquaintance led the development of the review’s guiding 
questions. An expert has been consulted to provide 
further input and feedback on our predefined set of core 
and subquestions. In line with our intention to compre-
hensively map and synthesise a potentially fast-growing 
and fragmented volume of literature on electronic 
PGHD, the review’s primary, overarching research ques-
tion is defined as: ‘What is our knowledge status, retrieved from 
existing literature, on the generation, collection, communication, 
sharing, interpretation, utilization, context and impact of elec-
tronic PGHD for the facilitation of patient/consumer-centered 
preventive activities and health promotion?’. Our question is 
focused on prevention or health promotion and targets 
adults. A comparator is not defined, as our search will not 
be restricted to studies with controls.
step 2: identifying relevant studies
The identification of relevant literature will consist of 
several combined approaches, including electronic data-
base searches and complementary activities, such as hand 
searches of selected online journals, relevant webpages, 
grey literature sources, reference list screening and 
expert consultations. Initially, we will systematically 
search seven electronic databases, including MEDLINE, 
CINAHL, PsycInfo, Scopus, Web of Science, Embase and 
IEEE Digital Library. Preliminary literature searches, 
consultation of thematically related reviews, input from 
the research team and the support of a specialised 
librarian led to predefined, preliminary search strategy, 
created on Embase and provided in online supplemen-
tary file 1. Our strategy is purposively sensitive, entailing 
a variety of keywords related to PGHD, restricted to 
adult populations and research published in the last 15 
years. Limiting our research to the last 15 years is based 
on our preliminary searches that indicate an emergence 
and accumulation of relevant literature during the last 
decade. We purposively added another 5 years to ensure 
that we capture all valuable literature and trends. The 
final strategy will be refined in a consultation with the 
experienced librarian who will run all searches. Retrieved 
documents will be imported into the electronic citation 
manager Mendeley.
Table 1 Targeted PGHD dimensions
Dimension Corresponding question and (hypothetical example)
PGHD generation How are PGHD created? (using a digital monitor to self-measure blood pressure)
PGHD collection How are PGHD captured and stored? (storing collected blood pressure values in an online patient 
portal)
PGHD communication and 
sharing
How are PGHD transferred? (using the patient portal to transfer blood pressure data to the general 
practitioner via secure email services)
PGHD interpretation How are PGHD reviewed and made sense of? (patient/provider views uploaded blood pressure 
measurements online over time to understand progress)
PGHD purposes What is the intended purpose for collecting and using electronic PGHD? (self-regulation and 
personalised feedback)
PGHD utilisation (a) How are PGHD applied for achieving desired results? What is their actual use? (online portal 
sends provider-initiated feedback emails, based on abnormal values)
(b) Is their actual use in line with the intended purposes?
PGHD context What are the settings/environments of PGHD use? (electronic blood pressure measurements taken 
at home and at the work place)
PGHD impact What are the effects or implications of PGHD? (control and course of blood pressure)
PGHD, patient-generated health data.
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In order to acquire the level of comprehensiveness 
required for a scoping review, we will also hand search 
key electronic journals, including the Journal of the 
American Medical Informatics Associaton (JAMIA), the 
Journal of Medical Internet Research (JIMR), the Inter-
national Journal of Digital Healthcare, Digital Health (SAGE) 
and the Journal of m-Health.39 Grey literature, such as 
reports, policy briefs, conference abstracts and theses will 
be retrieved through rigorous searches of the following 
sources: Grey Literature Report, Open Grey, Web of 
Science Conference Proceedings and Proquest Disserta-
tions. Ensuring that no relevant publication is missed, we 
will run several web engine searches using Google, Google 
Scholar and Yahoo and screening the first 10 result 
pages. Furthermore, we will screen thematically relevant 
webpages, such as the ONC, the Healthcare Information 
and Management Systems Society, the Patient-Centered 
Outcomes Research Institute, the Research Triangle Insti-
tute International, the Agency for Healthcare Research 
and Quality and Digital Health Canada. Our last research 
step consists of the manual reference list screening of all 
eligible studies as well as author consultations, requesting 
input on potentially missed or unpublished work.
step 3: study selection
The study selection process will consist of two phases, 
independently conducted by two members of the research 
team. The first author of this protocol, having previous 
experience with literature reviews and an educational back-
ground in digital health interventions for disease preven-
tion purposes, will take the first reviewer role. The second 
reviewer will be recruited based on substantial experience 
in planning and conducting literature reviews, an educa-
tional background in a health-related discipline and a 
good understanding of the proposed topic, preferably 
with previous work experience in a PGHD-related topic. 
Both will be responsible for independently completing 
the screening, selection and data extraction process, 
with the first reviewer having the added responsibility 
of data synthesis and final manuscript preparation. The 
first study selection phase includes the title and abstract 
screening of all identified documents. The second phase 
consists of full-text review of studies that have been classi-
fied as potentially eligible during phase one. During both 
phases, reviewers will assess study inclusion against a set of 
predefined eligibility criteria. To be eligible, studies have 
to have a clear focus on electronic PGHD, be linked to 
disease prevention and health promotion, address adult 
populations and include some reference to patient and 
provider involvement. The absence of elements or indi-
cators referring to prevention and health promotion (eg, 
reduction of blood pressure) or a shallow exploration of 
patient or provider attitudes towards PGHD and PGHD-
based tools, without being clearly defined within a preven-
tion or health promotion context, will lead to exclusion. 
To ensure that the chosen eligibility criteria are sensitive 
and clear in capturing relevant documents, they will be 
pretested by both reviewers on a sample of studies that 
have been identified during preliminary searches. Main-
taining a broad scope, our review will consider any type of 
primary research study designs as well as grey literature. 
Relevant systematic reviews will be considered as sources 
of potentially valuable primary research.
We will assess inter-rater agreement during both 
phases, using Cohen’s k coefficient.42 The coefficient, 
calculated after screening the first 50 titles and abstracts, 
will act as an indicator of whether both reviewers under-
stand and apply the inclusion criteria in an equal, 
correct and coherent manner. Low agreement (<0.40) 
will be followed by a consultation of the two reviewers, 
and if needed, adjustment or rewording of the eligibility 
criteria. This process will be repeated for the next 50 titles 
and abstracts and until inter-rater agreement reaches 
substantial levels (>0.40). After the title and abstract 
screening is completed, the two reviewers will meet to 
compare their results. Consulting the inclusion and exclu-
sion criteria, they will try to resolve conflicts and reach 
consensus on eligibility for full-text review. Studies that 
are unclear and do not allow for consensus will also enter 
full-text screening. During full-text review, which will be 
independently completed by the same two reviewers, 
inter-rater agreement will be calculated for the first 15 
studies. After completion of full-text screening, reviewers 
will meet again to compare their results. All discordant 
articles will be re-examined and persisting disputes will 
be resolved through consultation with a third reviewer, 
selected among one of the senior members of the 
research team (MM and MAP) and being responsible for 
the final decision on disputed papers. Both are members 
of Cochrane Public Health Europe and have consider-
able thematic and methodological knowledge. To ensure 
the highest levels of process transparency and reproduc-
ibility, the entire process will be captured and visualised 
in a Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) flow chart, including the most 
common exclusion reasons, as well as the final number of 
included documents.43
Box 2 provides the selected exclusion criteria, care-
fully chosen to guide the identification of eligible studies 
while counterbalancing the relatively high sensitivity 
that is inherent to the review’s broad research question. 
box 2 Exclusion criteria
1. Does not address the generation, collection, communication, shar-
ing, interpretation, utilisation, context or impact of electronic PGHD 
(as outlined in table 1).
2. Lacks a focus on prevention and health promotion (eg, exclusively 
addresses rehabilitation or therapeutic interventions).
3. Addresses patient-generated information that is not personal 
health related.
4. Does not describe, explore and analyse some form of patient and 
provider involvement.
5. Does not address or include adults.
6. Written in a language other than English or German.
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Documents that fulfil one or more of the statements 
below will be excluded.
step 4: charting the data
Data extraction will be conducted independently by two 
reviewers, guided by a predefined, however flexible, data 
extraction form. The preliminary form is developed by the 
research team and shown in table 2. It aims to ensure that 
all required information is captured practically, efficiently 
and accurately, minimising the risk of missing informa-
tion. Arksey and O’Malley’s methodological framework 
suggests charting the data according to central research 
themes.39 Thus, the chosen data extraction elements have 
been developed in line with the review’s objectives and 
corresponding research questions. Next to general infor-
mation, we aim to retrieve data on PGHD types, patient 
and provider responsibilities, PGHD impacts on disease 
prevention and health promotion and equity.
The final form will be refined and validated through 
consultations with the entire research team, as well as 
expert feedback. As suggested by Levac et al and Daudt 
et al, the form will be initially and independently tested 
by two reviewers on a random sample of five studies.40 44 
Table 2 Preliminary data charting elements
Element and subelement Associated question
Publication details
  Author and affiliation Who wrote the study/document?
  Type Is the document an empirical study or grey literature?
  Year What year was the study/document published?
  Country/region Which country is the study/document focusing on?
  Funding Are the funding sources provided?
  Conflict of interest declaration Is a conflict of interest statement included?
General details
  Methodological design What is the study/document design?
  Aims What are the study/document aims?
  Population Which is the target population of the study/document?
  Addressed condition(s), risk factors(s), symptom(s), 
behaviour(s) or outcome measure(s)
What is the health-related focus of the study/document?
  Setting What is the described setting?
  Perspective (promotion/prevention) Is the focus on prevention or health promotion?
Content
Patient roles and activities
 ► PGHD generation
 ► PGHD transfer and use
 ► Context
 ► Barriers and facilitators
What are the patient roles and required activities in generating, 
transferring and using electronic PGHD for prevention/health promotion 
purposes?
PGHD types
 ► Architecture
 ► Aims and purposes
What types of PGHD are addressed? What PGHD-based tools are 
used? What are the intended PGHD purposes?
Provider roles and activities
 ► PGHD integration
 ► PGHD use
 ► Purposes and use
 ► Context
 ► Barriers and facilitators
What are the provider roles and required activities in integrating and 
using electronic PGHD for prevention/health promotion purposes?
Is the actual PGHD use in line with the indented purposes?
Interactivity
 ► Barriers and facilitators
How do electronic PGHD affect or relate to patient–provider, as well as 
patient–technology interaction?
Impact on prevention and health promotion-related 
outcomes
What is the impact of electronic PGHD use on any outcomes related to 
prevention and health promotion?
Equity considerations Does the study/document address, explore or refer to actual or 
potential equity-related implications of PGHD (eg, better results for 
disadvantaged social groups)?
Other important results Further important results?
PGHD, patient-generated health data.
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This phase is described as as key to improving the quality 
and applicability of the data extraction chart.44 It will be 
followed by consultation to ensure accuracy, consistency 
and that the captured information contributes to the 
study’s research questions. Consultation might finally 
lead to form modifications that have to be reviewed and 
agreed on by the entire research team.
After completion of the full data extraction process, 
both reviewers’ final data sets will be compared. Each 
article will have a unique identification number to 
enhance process efficiency and practicality. Inconsisten-
cies and disagreements will be discussed, reconsulting 
the respective documents and if necessary, requesting 
support by a senior investigator of the team (MM and 
MAP).
step 5: collating, summarising and reporting the results
As described by Arksey and O’Malley, a weighted data 
synthesis and aggregation of findings is not inherently 
essential to a scoping review, considering the missing 
assessment of evidence quality and robustness.39 The 
chosen analytical approach will therefore be of narrative 
nature, guided by the adapted PGHD flow framework 
(figure 1) and the review’s objectives.17 Despite its bene-
fits, a quality assessment will not be performed as it does 
not align with our aim of scoping a potentially large and 
heterogeneous literature volume.
Initial synthesis will be of basic quantitative nature, 
summarising the extent, scope and nature of existing 
literature. Publication types, years, geographic distri-
bution, target populations, target conditions, risks 
and behaviours, as well as existing methodologies will 
be synthesised descriptively, using ranges and counts, 
presented in tables. That step will provide an overview of 
existing evidence and research activity trends, as well as 
highlight potential research gaps.39
Further synthesis will remain narrative but also 
consider quantitative primary data. Tables and figures will 
summarise key findings, structured around the review’s 
objectives. The research team and experts will enrich 
data synthesis through regular input, ensuring validity 
and transparency. With exception of the risk of bias and 
evidence strength (GRADE) assessment, the reporting of 
our results will be guided by the PRISMA reporting guide-
lines.45 The entire process, including screening (step 3), 
data extraction (step 4) and synthesis will be conducted 
with the Covidence Software and Excel. We are not plan-
ning any additional analyses.
step 6: consultation
Levac et al, pointed out that consultation, the sixth trans-
versal optional stage of the scoping studies framework, 
may enable stakeholder engagement and provide valu-
able input, beyond the information provided in the liter-
ature.40 As already described throughout the protocol, 
expert consultation is central at all stages of this study. An 
external expert in the area of PGHD has been consulted 
twice during the development of this protocol, providing 
conceptual and content-related feedback and advice. 
During the review process, we will additionally establish 
regular consultation with one provider–partner and at 
least one patient–partner. Both stakeholders will be asked 
to provide feedback during data extraction, appraisal of 
preliminary results, data synthesis and interpretation. 
Finally, we aim to engage digital health experts within the 
team’s own institution for additional advice. All involved 
experts and stakeholders will be acknowledged in the 
final publication.
Patient and public involvement
There was no patient or public involvement in the 
design of this protocol. Nonetheless, as outlined in the 
previous paragraph, at least one patient advisor will 
be consulted during the implementation stages of our 
review, asked to provide feedback on the clarity, appli-
cability and value of the review’s findings and interpre-
tations. Any involved patient–partner will receive our 
preliminary and final results electronically and during 
consultations.
EthICs And dIssEMInAtIon
The described review constitutes the first step of a larger 
research project on digital solutions for disease preven-
tion and health promotion. Its results ultimately fulfil 
the function of establishing a comprehensive concep-
tual knowledge of electronic PGHD and will be used to 
inform prospective research steps. As we did not expect 
or receive any search strategy modifications, searches 
have been run during January 2018. All other review 
steps commenced from mid-February 2018 onward, 
incorporating all reviewer comments. Findings will be 
disseminated at relevant conferences and symposia. 
Results will be published and additionally shared with 
our provider and patient–partners and their networks, 
as well as local and national organisations operating 
in the field of digital health. As our methodology is 
based on the review of publicly available information, 
ethical approval is not required. Any amendments to 
this protocol will be documented precisely and listed in 
the final review publication.
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